Screener
Cytokinetics CYTK Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Derivative liabilities measured at fair value | 30,700 | 31,100 |
| Deferred revenue | 1,653 | 1,612 |
| Other current liabilities | 3,304 | 3,833 |
| Total current liabilities | 181,429 | 202,452 |
| Term loans, net | 248,202 | 246,384 |
| Convertible notes, net | 871,527 | 869,597 |
| Liabilities related to revenue participation right purchase agreements, net | 558,054 | 520,559 |
| Long-term operating lease liabilities | 102,426 | 107,970 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's total current liabilities?
- Cytokinetics (CYTK) reported total current liabilities of $181.43M in Q2 2026.
- How has Cytokinetics's total current liabilities changed year-over-year?
- Cytokinetics's total current liabilities increased by 38.4% year-over-year, from $131.06M to $181.43M.
- What is the long-term trend for Cytokinetics's total current liabilities?
- Over 5 years (2020 to 2025), Cytokinetics's total current liabilities has grown at a 45.4% compound annual growth rate (CAGR), from $31.2M to $202.45M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Cytokinetics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude